+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Pulmonary Arterial Hypertension Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F

  • PDF Icon

    Report

  • 170 Pages
  • October 2023
  • Region: Global
  • TechSci Research
  • ID: 5893461
Free Webex Call
10% Free customization
Description Jump to:
Free Webex Call

Speak directly to the analyst to clarify any post sales queries you may have.

 10% Free customization

This report comes with 10% free customization, enabling you to add data that meets your specific business needs.
The Global Pulmonary Arterial Hypertension (PAH) Market reached a valuation of USD 6.66 Billion in 2022 and is expected to experience substantial growth throughout the forecast period, projecting a Compound Annual Growth Rate (CAGR) of 5.32% and expected to reach USD 9.06 Billion through 2028. Pulmonary Arterial Hypertension is a rare but serious medical condition characterized by elevated blood pressure in the pulmonary arteries, which carry blood from the heart to the lungs. This condition leads to the narrowing and stiffening of these arteries, placing increased strain on the heart and potentially resulting in heart failure.

The Global Pulmonary Arterial Hypertension (PAH) Market encompasses various pharmaceuticals, medical devices, and treatment strategies designed to manage and address PAH. Recent developments in medical understanding, innovative therapies, and heightened awareness of PAH have been key drivers of growth in this market. Factors contributing to this growth include the increasing prevalence of PAH due to risk factors like sedentary lifestyles and obesity, as well as improved diagnostic capabilities and heightened awareness among both patients and healthcare professionals.

Pharmaceutical interventions play a pivotal role in managing PAH, with drugs targeting specific pathways associated with the disease's pathogenesis. These medications, such as prostacyclin analogs, endothelin receptor antagonists, and phosphodiesterase type 5 inhibitors, aim to dilate blood vessels, reduce arterial pressure, and alleviate symptoms like fatigue and shortness of breath.

Moreover, medical devices like pulmonary vasodilator pumps and implantable devices like ventricular assist devices contribute to managing severe cases of PAH. Alongside conventional therapies, lifestyle modifications and regular exercise are recommended to enhance patients' quality of life. However, challenges persist within the PAH market, including the high cost of treatment and limited access to specialized care. Additionally, the complexity of PAH diagnosis and the need for specialized expertise can hinder timely intervention.

The outlook of the market is characterized by ongoing research and development efforts focused on discovering novel therapies and improving treatment outcomes. Emerging trends such as personalized medicine approaches, biomarker identification, and combination therapies show promise in tailoring treatments to individual patient needs.

In conclusion, the Global Pulmonary Arterial Hypertension (PAH) Market is undergoing significant transformation due to innovative therapies and medical advancements. As awareness of the condition increases and research continues, the market is poised to witness further developments in diagnostics, treatment options, and patient care, ultimately leading to improved outcomes for those affected by this challenging medical condition.

Key Market Drivers

1. Increasing Prevalence and Awareness of PAH: The rising prevalence of PAH and growing awareness of its severity have driven the expansion of the PAH Market. Public health campaigns, improved medical education, and patient advocacy initiatives have contributed to early diagnosis and intervention.

2. Innovative Therapeutic Approaches: Pharmaceutical advancements targeting PAH's underlying mechanisms have transformed the treatment landscape. Innovative drugs and medical devices are improving patient outcomes and quality of life.

3. Personalized Medicine: Tailoring medical care to individual patient profiles is a significant trend. Genetic testing, molecular profiling, and targeted therapies optimize treatment efficacy and patient engagement.

Key Market Challenges

1. High Treatment Costs: The cost of PAH medications, medical devices, and specialized care poses financial challenges for patients and healthcare systems. Access to effective treatments and comprehensive care can be compromised.

2. Limited Awareness: Lack of awareness among patients and healthcare professionals leads to delayed diagnosis, suboptimal care, and limited research funding. Raising awareness through education and advocacy is crucial.

3. Patent Expiration of Key Drugs: Patent expiration affects treatment accessibility, affordability, and innovation. Balancing patients' access to affordable treatments with pharmaceutical innovation is essential.

Key Market Trends

1. Collaborative Research and Global Networks: International partnerships and networks facilitate knowledge exchange, interdisciplinary approaches, and accelerated development of innovative therapies and treatment guidelines.

2. Personalized Treatment Approaches: Personalized medicine, driven by genetics and molecular profiles, is transforming PAH care. Precise diagnostics and targeted therapies enhance treatment efficacy and patient empowerment.

Segmental Insights

1. Drug Class Insights: Phosphodiesterase 5 inhibitors, such as sildenafil and tadalafil, dominate the PAH Market due to their ability to relax pulmonary blood vessels and alleviate symptoms.

2. Type Insights: Branded medications, with established efficacy and safety records, continue to be the primary choice in PAH treatment, despite the availability of generics.

Regional Insights

North America leads the PAH Market due to advanced healthcare infrastructure, robust research initiatives, and regulatory support. Collaborations among medical institutions, awareness campaigns, and patient advocacy efforts contribute to improved disease management and outcomes in the region.

Key Market Players

  • Gilead Sciences, Inc.
  • Viatris Inc.
  • Sandoz Inc. (Novartis)
  • Johnson & Johnson
  • Sun Pharmaceutical Industries, Inc.
  • Lupin Pharmaceuticals, Inc.
  • GlaxoSmithKline LLC
  • Johnson & Johnson
  • Bayer AG
  • United Therapeutics Corporation

Report Scope:

In this report, the Global Pulmonary Arterial Hypertension Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pulmonary Arterial Hypertension Market, By Drug Class:

  • Prostacyclin and Prostacyclin Analogs
  • Calcium Channel Blockers
  • Phosphodiesterase 5
  • Endothelin Receptor Antagonist
  • Others

Pulmonary Arterial Hypertension Market, By Type:

  • Branded
  • Generics

Pulmonary Arterial Hypertension Market, By Route Of Administration:

  • Oral
  • Intravenous/ Subcutaneous
  • Inhalational

Global Pulmonary Arterial Hypertension Market, By region:

  • North America
  • United States
  • Canada
  • Mexico
  • Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pulmonary Arterial Hypertension Market.

Available Customizations:

Global Pulmonary Arterial Hypertension Market report with the given market data, the publisher offers customizations according to a company's specific needs.


This product will be delivered within 1-3 business days.

Table of Contents

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customers
5. Global Pulmonary Arterial Hypertension Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Drug Class (Prostacyclin and Prostacyclin Analogs, Calcium Channel Blockers, Phosphodiesterase 5, Endothelin Receptor Antagonist and Others)
5.2.2. By Type (Branded, Generics)
5.2.3. By Route Of Administration (Oral, Intravenous/ Subcutaneous, Inhalational)
5.2.4. By Company (2022)
5.2.5. By Region
5.3. Market Map
6. North America Pulmonary Arterial Hypertension Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Drug Class
6.2.2. By Type
6.2.3. By Route Of Administration
6.2.4. By Country
6.3. North America: Country Analysis
6.3.1. United States Pulmonary Arterial Hypertension Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Drug Class
6.3.1.2.2. By Type
6.3.1.2.3. By Route Of Administration
6.3.2. Mexico Pulmonary Arterial Hypertension Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Drug Class
6.3.2.2.2. By Type
6.3.2.2.3. By Route Of Administration
6.3.3. Canada Pulmonary Arterial Hypertension Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Drug Class
6.3.3.2.2. By Type
6.3.3.2.3. By Route Of Administration
7. Europe Pulmonary Arterial Hypertension Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Drug Class
7.2.2. By Type
7.2.3. By Route Of Administration
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. France Pulmonary Arterial Hypertension Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Drug Class
7.3.1.2.2. By Type
7.3.1.2.3. By Route Of Administration
7.3.2. Germany Pulmonary Arterial Hypertension Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Drug Class
7.3.2.2.2. By Type
7.3.2.2.3. By Route Of Administration
7.3.3. United Kingdom Pulmonary Arterial Hypertension Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Drug Class
7.3.3.2.2. By Type
7.3.3.2.3. By Route Of Administration
7.3.4. Italy Pulmonary Arterial Hypertension Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Drug Class
7.3.4.2.2. By Type
7.3.4.2.3. By Route Of Administration
7.3.5. Spain Pulmonary Arterial Hypertension Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Drug Class
7.3.5.2.2. By Type
7.3.5.2.3. By Route Of Administration
8. Asia-Pacific Pulmonary Arterial Hypertension Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Drug Class
8.2.2. By Type
8.2.3. By Route Of Administration
8.2.4. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Pulmonary Arterial Hypertension Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Drug Class
8.3.1.2.2. By Type
8.3.1.2.3. By Route Of Administration
8.3.2. India Pulmonary Arterial Hypertension Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Drug Class
8.3.2.2.2. By Type
8.3.2.2.3. By Route Of Administration
8.3.3. South Korea Pulmonary Arterial Hypertension Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Drug Class
8.3.3.2.2. By Type
8.3.3.2.3. By Route Of Administration
8.3.4. Japan Pulmonary Arterial Hypertension Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Drug Class
8.3.4.2.2. By Type
8.3.4.2.3. By Route Of Administration
8.3.5. Australia Pulmonary Arterial Hypertension Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Drug Class
8.3.5.2.2. By Type
8.3.5.2.3. By Route Of Administration
9. South America Pulmonary Arterial Hypertension Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Drug Class
9.2.2. By Type
9.2.3. By Route Of Administration
9.2.4. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Pulmonary Arterial Hypertension Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Drug Class
9.3.1.2.2. By Type
9.3.1.2.3. By Route Of Administration
9.3.2. Argentina Pulmonary Arterial Hypertension Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Drug Class
9.3.2.2.2. By Type
9.3.2.2.3. By Route Of Administration
9.3.3. Colombia Pulmonary Arterial Hypertension Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Drug Class
9.3.3.2.2. By Type
9.3.3.2.3. By Route Of Administration
10. Middle East and Africa Pulmonary Arterial Hypertension Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Drug Class
10.2.2. By Type
10.2.3. By Route Of Administration
10.2.4. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Pulmonary Arterial Hypertension Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Drug Class
10.3.1.2.2. By Type
10.3.1.2.3. By Route Of Administration
10.3.2. Saudi Arabia Pulmonary Arterial Hypertension Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Drug Class
10.3.2.2.2. By Type
10.3.2.2.3. By Route Of Administration
10.3.3. UAE Pulmonary Arterial Hypertension Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Drug Class
10.3.3.2.2. By Type
10.3.3.2.3. By Route Of Administration
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions
13. PESTLE Analysis
14. Porter’s Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Product
15. Competitive Landscape
15.1. Business Overview
15.2. Company Snapshot
15.3. Product & Services
15.4. Financials (In case of listed companies)
15.5. Recent Developments
15.6. SWOT Analysis
15.6.1. Gilead Sciences, Inc.
15.6.2. Viatris Inc.
15.6.3. Sandoz Inc. (Novartis)
15.6.4. Johnson & Johnson
15.6.5. Sun Pharmaceutical Industries, Inc.
15.6.6. Lupin Pharmaceuticals, Inc.
15.6.7. GlaxoSmithKline LLC
15.6.8. Johnson & Johnson
15.6.9. Bayer AG
15.6.10. United Therapeutics Corporation
16. Strategic Recommendations

Companies Mentioned

  • Gilead Sciences, Inc.
  • Viatris Inc.
  • Sandoz Inc. (Novartis)
  • Johnson & Johnson
  • Sun Pharmaceutical Industries, Inc.
  • Lupin Pharmaceuticals, Inc.
  • GlaxoSmithKline LLC
  • Johnson & Johnson
  • Bayer AG
  • United Therapeutics Corporation

Table Information

Report AttributeDetails
No. of Pages170
PublishedOctober 2023
Forecast Period2023 - 2028
Estimated Market Value ( USD ) in 2023 $ 6.66 Billion
Forecasted Market Value ( USD ) by 2028 $ 9.06 Billion
Compound Annual Growth Rate5.3%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Pulmonary Arterial Hypertension Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa) - Product Image

Pulmonary Arterial Hypertension Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • Report
  • 250 Pages
  • Global
Pulmonary Arterial Hypertension Drugs Market Report by Drug Class, Route of Administration, End User, and Region 2024-2032 - Product Image

Pulmonary Arterial Hypertension Drugs Market Report by Drug Class, Route of Administration, End User, and Region 2024-2032

  • Report
  • 146 Pages
  • Global
From
Pulmonary Arterial Hypertension Market by Drug Class, Distribution - Global Forecast 2025-2030 - Product Image

Pulmonary Arterial Hypertension Market by Drug Class, Distribution - Global Forecast 2025-2030

  • Report
  • 196 Pages
  • Global
From
Pulmonary Arterial Hypertension (PAH) Drugs Market 2024-2028 - Product Image

Pulmonary Arterial Hypertension (PAH) Drugs Market 2024-2028

  • Report
  • 180 Pages
  • Global
From
Pulmonary Hypertension - Pipeline Insight, 2024 - Product Image

Pulmonary Hypertension - Pipeline Insight, 2024

  • Clinical Trials
  • 80 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.